[Two cases of stage IV gastric cancer responding to chemotherapy with S-1 or UFT].
We report patients with advanced Stage IV gastric cancer responding to chemotherapy with S-1 or UFT. Case 1: The patient was a 59-year-old man with Stage IV gastric cancer because of CY 1. After surgery, chemotherapy with S-1 (100 mg/body/day) was performed for one year and 11 months. At present, 5 years and 5 months after surgery, this patient shows no signs of tumor recurrence. Case 2: The patient was a 68-year-old woman with Stage IV gastric cancer because of P 1. She was treated with 200 mg/day of UFT for one year and 9 months. At present, 5 years after surgery, she shows no signs of tumor recurrence. We considered that the longterm survival of such patients is attributable to chemotherapy with S-1 or UFT. The OPRT activity of the two cases was high, so chemotherapy with S-1 or UFT was thought to be effective for them.
Nakamura
Yukio
Y
Department of Surgery, Osaka Kosei-Nenkin Hospital.
Yumiba
Takeyoshi
T
Yamasaki
Yoshio
Y
Momiyama
Takuya
T
Ito
Akira
A
Akamaru
Yusuke
Y
Sugimoto
Youko
Y
Tamaoka
Noriko
N
Beppu
Naohito
N
Watanabe
Yusuke
Y
Ohno
Kiyoshi
K
Kasugai
Tsutomu
T
D000230:Adenocarcinoma / Q000188:drug therapy*; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000627:therapeutic use*; D014498:Uracil / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D014498:Uracil; D010094:Oxonic Acid